What Excel Diagnostic Imaging Clinics does

Excel Diagnostics & Nuclear Oncology Center (EDNOC), founded circa 2004 by Ebrahim S. Delpassand, MD, is a privately held outpatient diagnostic imaging and nuclear therapeutic facility operating from a single location at 9701 Richmond Ave Suite 122 in Houston, Texas. The center delivers a full suite of imaging modalities — PET/CT, SPECT/CT, MRI, CT, Digital X-Ray, DEXA, and Ultrasound — alongside a broad radiopharmaceutical therapy program including I-131 for thyroid disease, Lutathera (Lu-177) for neuroendocrine tumors, and Pluvicto (Lu-177 PSMA) for metastatic castration-resistant prostate cancer, plus investigational agents under Expanded Access Programs. It also administers a consumer-paid Wellness Direct Program for preventive screening and runs 10+ sponsored clinical trials in radiopharmaceuticals in collaboration with academic institutions, CROs, and pharmaceutical sponsors under GCP/CITI-trained staff.

The facility is designated as a Radiopharmaceutical Therapy Center of Excellence (RTCOE) by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) since 2020 — among the first private outpatient U.S. sites to obtain this status — and serves as a pioneer in introducing several new diagnostic and therapeutic radiopharmaceuticals to the United States, with strategic alignment to sister company RadioMedix. Its technology stack includes AI-augmented MRI analysis modules (icobrain ARIA and icobrain DM) for Alzheimer's and dementia monitoring, patient portal access via Purview, physician portal via RamSoft PACS, and CareCredit-enabled patient financing.

Revenue is generated across four transaction-based streams: (1) fee-for-service diagnostic imaging paid via Medicare, commercial insurance, or cash; (2) per-cycle radionuclide therapy billing; (3) the Wellness Direct Program paid out-of-pocket by patients; and (4) professional services revenue from sponsored clinical trial conduct. Distribution is direct to patients through physician referrals, walk-ins, and self-pay channels, with no retail or online distribution beyond portal-based scheduling and results access. The company maintains a 4.8 Google rating across 162 reviews and reports 10,000+ satisfied patients served over its operating history.

Name

Excel Diagnostic Imaging Clinics

Legal name

Excel Diagnostics & Nuclear Oncology Center

Website

https://exceldiagnostics.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

Excel Diagnostics & Nuclear Oncology Center is a private outpatient diagnostic imaging and nuclear medicine facility in Houston, Texas, offering PET/CT, MRI, CT, radionuclide therapies, and sponsored clinical trials to cancer, Alzheimer's, and chronic disease patients via physician referrals and self-pay.

Ownership category

akta.pro rank

Product category

Diagnostic Imaging Services

NAICS

Diagnostic Imaging Centers (621512), Medical and Diagnostic Laboratories (62151)

SIC

Services-Specialty Outpatient Facilities, Nec (8093), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Advanced Imaging & Specialty Radiology Centers (PET/CT, Nuclear Medicine, Interventional Radiology) (HLAFAKAB)

akta.pro secondary industries

Nuclear Medicine Clinical Services & Therapy Centers (HLAIAGAI), Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI)

Keywords

• Diagnostic imaging services
• Nuclear medicine therapy
• Radiopharmaceutical therapy
• PET CT imaging
• Nuclear oncology center

Headquarters

HQ city

Houston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Diagnostic Imaging Services: Provides PET/CT, CT, MRI, SPECT/CT, Digital X-Ray, DEXA Bone Density, Ultrasound, and Nuclear Medicine scans on fee-for-service basis. Accepts Medicare, most commercial insurance, and offers competitive cash pricing.
2. Radionuclide/Radioisotope Therapy: Therapeutic treatments including I-131 for thyroid conditions, Lutetium-177 (Lutathera) for neuroendocrine tumors, Pluvicto (Lu-177 PSMA) for prostate cancer, and Actinium-225 PSMA therapy. Billed per treatment cycle.
3. Wellness Direct Program: Comprehensive medical assessment program using multi-modality diagnostic imaging and laboratory services for early detection. Pre-payment required as insurance typically does not cover. Multiple panel options including Cancer, Heart Disease/Stroke, Bone/Rheumatic, Comprehensive Health, and Diabetes panels.
4. Clinical Research Trials: Conducts sponsored clinical research trials in radiopharmaceuticals and nuclear medicine. Budget provided in less than 2 weeks for clinical trial protocols. Revenue from pharmaceutical company sponsors for trial conduct.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Excel Diagnostics & Nuclear Oncology Center operates as an outpatient diagnostic imaging and nuclear therapeutic facility in Houston, TX. It provides PET/CT, MRI, CT, SPECT/CT, DEXA, ultrasound, and digital X-ray imaging services alongside targeted radiopharmaceutical therapies (I-131, Lutathera, Pluvicto, Ac-225 PSMA) and a Wellness Direct preventive screening program. It also conducts sponsored clinical trials in nuclear medicine and radiopharmaceuticals.

Product overview

Excel Diagnostics & Nuclear Oncology Center operates as a diagnostic imaging and nuclear therapeutic facility offering a comprehensive portfolio of imaging services and radiopharmaceutical treatments. The core diagnostic offerings include PET/CT, CT/CAT Scan, MRI (including AI-powered variants like MRI Icobrain ARIA and MRI Icobrain DM), Digital X-Ray, DEXA Bone Density, Nuclear Medicine SPECT/CT, Ultrasound, and Nuclear Stress Testing. The therapeutic portfolio encompasses radionuclide therapies including Radioactive Iodine (I-131), Lutathera (Lu-177), and Pluvicto (Lu-177). They also offer an array of PET tracers including FDG, Gallium Ga 68 PSMA, DetectNet, NetSpot, Amyvid, Cerianna, and DaTscan. The center operates a Wellness Direct Program for preventive health assessments and a Clinical Trials department conducting radiopharmaceutical research. The facility provides patient and physician portal access through third-party integrations for result management.

Differentiator

Problem solved

Functional benefit

Products and services

• PET/CT Scan Combines Positron Emission Tomography (PET) and Computed Tomography (CT) imaging to provide detailed information about the structure and function of tissues and organs, commonly used for cancer detection.
• CAT Scan (CT) Uses X-ray technology and computer imaging to create detailed cross-sectional images of the body including bones, blood vessels, and soft tissues.
• DEXA (Bone Density) Dual-Energy X-ray Absorptiometry scan that measures bone mineral density to assess fracture risk and osteoporosis.
• Digital X-Ray Advanced form of X-ray imaging using digital sensors instead of traditional photographic film for immediate image preview.
• MRI Magnetic Resonance Imaging using strong magnetic field and radio waves to create detailed images of organs and tissues without ionizing radiation.
• MRI Icobrain ARIA AI-powered brain MRI monitoring exam using icobrain ARIA software to detect, measure, and track amyloid-related imaging abnormalities (ARIA-E and ARIA-H) in patients receiving Alzheimer's therapies.
• MRI Icobrain DM AI-assisted brain MRI exam using icobrain DM software to evaluate and monitor brain changes associated with dementia and neurodegenerative conditions.
• Nuclear Medicine SPECT/CT Combines Single-Photon Emission Computed Tomography (SPECT) with CT to provide both functional and anatomical information for enhanced diagnostic accuracy.
• Radionuclide Therapy Radioisotope therapy using radioactive substances to target and destroy cancer cells while minimizing damage to surrounding healthy tissue, including I-131, Lutathera, and Pluvicto treatments.
• Nuclear Medicine Stress Test Evaluates blood flow to the heart both at rest and during stress to diagnose coronary artery disease and other heart conditions.
• Ultrasound Non-invasive imaging technique using high-frequency sound waves to create real-time images of internal body structures without radiation.
• Wellness Direct Program Comprehensive annual wellness assessment program using multi-modality diagnostic imaging and laboratory services for early detection of medical conditions including cancer, heart disease, and osteoporosis.
• Clinical Trials Clinical research program conducting sponsored trials in radiopharmaceuticals and nuclear medicine procedures with GCP-trained staff and board-certified investigators.

Quantifiable outcome

• 10,000+ satisfied patients served
• +4 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability5 records

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• Monopar Therapeutics Inc.coreStrategic or Co-development Partner · 11 June 2025Clinical collaboration for Expanded Access Program (EAP) for investigational imaging agent MNPR-101-Zr (zirconium-89) and therapeutic agent MNPR-101-Lu (lutetium-177) targeting uPAR-expressing solid tumors including triple-negative breast, pancreatic, and colorectal cancer. EDNOC provides treatment site and clinical expertise under supervision of Dr. Ebrahim S. Delpassand. Monopar provides investigational radiopharmaceutical products.
• RadioMedixcoreStrategic or Co-development PartnerSister company relationship. RadioMedix developed Detectnet (Cu-64 DOTATATE), included in NCCN Clinical Practice Guidelines for Neuroendocrine and Adrenal Tumors. EDNOC offers Detectnet PET/CT for NET diagnosis. Dr. Ebrahim Delpassand serves as CEO of RadioMedix.
• Academic Institutions and Pharmaceutical CompaniescoreStrategic or Co-development PartnerEDNOC conducts sponsored clinical research trials in radiopharmaceuticals and nuclear medicine procedures for academic institutions and pharmaceutical companies. Works closely with CROs and IRB. ECRD team provides project coordination, technologist training, and management of data and report forms in full compliance with FDA, GCP, ICH and IRB guidelines.
• Society of Nuclear Medicine and Molecular Imaging (SNMMI)coreOthersSNMMI designated EDNOC as Radiopharmaceutical Therapy Center of Excellence (RTCOE) since 2020. This designation recognizes excellence in radiopharmaceutical therapy and positions EDNOC among leading nuclear medicine facilities nationally.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Akumin: Outpatient diagnostic imaging chain operating fixed-site centers with MRI, CT, PET/CT, and nuclear medicine. Direct competitor in the outpatient imaging category where EDNOC operates.
• RadNet: Largest U.S. outpatient imaging network with ~370 centers, offering MRI, CT, PET/CT, and related services. Comparable to EDNOC's core diagnostic imaging business at vastly greater scale.
• Center for Diagnostic Imaging (CDI): Outpatient imaging network offering MRI, CT, PET/CT, and women's imaging. Comparable outpatient imaging business model, though broader geographic footprint.
• SimonMed Imaging: One of the largest U.S. outpatient imaging networks, including PET/CT and MRI. Competitor for physician referrals and self-pay imaging patients, particularly in Texas-adjacent markets.
• Curium: Global nuclear medicine company producing diagnostic and therapeutic radiopharmaceuticals. Supplier-comparator relevant to EDNOC's PET tracer sourcing and therapy operations.
• US Radiology Specialists: National outpatient imaging platform (subsidiary of Bain Capital) with fixed sites, teleradiology, and women's imaging. Direct comparator in the multi-site outpatient imaging model EDNOC could aspire to.
• Lantheus Holdings: Major radiopharmaceutical manufacturer (DEFINITY, PYLARIFY, Point Biopharma acquisition). Strategic comparator and upstream supplier — Lantheus-developed agents underpin much of EDNOC's PET/CT and Lu-177 therapy volume.

Emerging players

• Monopar Therapeutics: Clinical-stage radiopharma company partnered with EDNOC on the MNPR-101 Expanded Access Program. Partner-comparable due to overlapping theranostics focus and clinical pipeline in uPAR-expressing cancers.
• Telix Pharmaceuticals: Commercial-stage radiopharma company with Illuccix (Ga-68 PSMA) and a growing theranostics pipeline. Peer in the broader theranostics ecosystem where EDNOC serves as a treatment/imaging site.

Regional players

• Touchstone Imaging: Outpatient imaging operator with centers across Texas and the South, including MRI, CT, and PET/CT. Geographic competitor in the same regional referral ecosystem as EDNOC's Houston facility.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@exceldiagnosticscenter
• Facebookfacebook.com/profile.php?id=100065187210706
• LinkedInlinkedin.com/company/excel-diagnostics-nuclear-oncology-center/mycompany/?viewAsMember=true
• Instagraminstagram.com/excel_diagnostics_center/?fbclid=IwZXh0bgNhZW0CMTEAAR23Ki-qPQx78oPe_2RfADvl-DF-xY6klRiHk5Abxu9YT-oEcHnwQMvLAko_aem_V5Hy33dihABeHto9hZGNdA
• Xx.com/exceldiagnostic

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Excel Diagnostic Imaging Clinics